Compositions and methods for treating estrogen-related medical disorders
Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.
1. A compound having formula (I-vii)
wherein
R 1 is selected from the group consisting of hydrogen, alkyl, —SO 3 R x1 , —PO 3 R y1 R z1 , and —C(═O)R a ;
R 2 is selected from the group consisting of halo and —OR 3 ;
R 3 is selected from the group consisting of hydrogen, alkyl, —SO 3 R x1 , —PO 3 R y1 R z1 , and —C(═O)R a ;
R 4 is selected from the group consisting of hydrogen, alkyl, —SO 3 R x1 , —PO 3 R y1 R z1 , and —C(═O)R a ;
R a , at each occurrence, is independently selected from the group consisting of —OH and alkyl; and
R x1 , R y1 and R z1 are, at each occurrence, independently selected from the group consisting of hydrogen and a pharmaceutically acceptable cation.
2. The compound of claim 1 , having formula (I-viii),
wherein R 1 and R 4 are as defined in claim 1 .
3. The compound of claim 1 , having formula (I-ix),
wherein R 1 is as defined in claim 1 .
4. The compound of claim 1 , having formula (I-x),
5. A pharmaceutical composition comprising a compound of formula (I-vii) according to claim 1 , and a pharmaceutically acceptable carrier.
6. A compound selected from the group consisting of:
3-(4-fluorophenyl)-2-(4-hydroxyphenoxyl)benzo[b]thiophen-6-ol; and
4-((3-(4-fluorophenyl)-6-methoxybenzo[b]thiophen-2-yl)oxy)phenol;
or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition, comprising a compound according to claim 6 , and a pharmaceutically acceptable carrier.